Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Consensus Rating of “Reduce” from Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been assigned an average recommendation of “Reduce” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $28.63.

A number of analysts have recently issued reports on the company. Truist Financial reduced their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a report on Tuesday, July 30th. JMP Securities lowered their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Citigroup lowered their price target on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a research report on Thursday, August 22nd. Morgan Stanley increased their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Finally, BTIG Research cut their price target on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a research note on Wednesday, August 28th.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $17.40 on Monday. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. The business has a 50 day moving average of $22.69 and a two-hundred day moving average of $27.79. The company has a market cap of $1.37 billion, a P/E ratio of 34.80, a PEG ratio of 0.60 and a beta of 1.10. Integra LifeSciences has a 52 week low of $16.96 and a 52 week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The firm had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. During the same quarter in the previous year, the company earned $0.71 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in IART. State of Michigan Retirement System increased its stake in shares of Integra LifeSciences by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after purchasing an additional 400 shares during the last quarter. CWM LLC increased its stake in shares of Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 425 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the last quarter. Amalgamated Bank increased its stake in shares of Integra LifeSciences by 1.2% during the 1st quarter. Amalgamated Bank now owns 45,103 shares of the life sciences company’s stock worth $1,599,000 after purchasing an additional 533 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its stake in shares of Integra LifeSciences by 1.1% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock worth $1,764,000 after purchasing an additional 551 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.